# SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients

> **NCT05313074** · NA · COMPLETED · sponsor: **National Cancer Institute, Thailand** · enrollment: 311 (actual)

## Conditions studied

- COVID-19
- Cancer

## Interventions

- **BIOLOGICAL:** CoronaVac vaccine

## Key facts

- **NCT ID:** NCT05313074
- **Lead sponsor:** National Cancer Institute, Thailand
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-23
- **Primary completion:** 2022-02-25
- **Final completion:** 2022-02-25
- **Target enrollment:** 311 (ACTUAL)
- **Last updated:** 2022-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05313074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05313074, "SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05313074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*